Previous 10 | Next 10 |
home / stock / rvnc / rvnc articles
AbbVie Inc (NYSE:ABBV) remains confident in Botox’s resilience in the aesthetics market, assured by its ability to sustain a dominant 68...
Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guida...
U.S. stocks traded mixed, with the Dow Jones index falling around 80 points on Monday. Shares of The Boeing Company (NYSE: BA) fell during Friday&r...
Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares climbed 83.5% to $0.4169 after reporting first-quarter results. Astra Space, Inc. (N...
U.S. stock futures traded mostly higher this morning on Thursday. Here are some big stocks recording losses in today’s pre-market trading ses...
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance...
NEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revanc...
Needham analyst Serge Belanger reiterated a Buy rating on Revance Therapeutics, Inc. (NASDAQ: RVNC), lowering the price target ...
Rosenblatt increased the price target for Pinterest, Inc. (NYSE: PINS) from $35 to $38. Rosenblatt analyst Barton Crockett maintained a Buy rati...
News, Short Squeeze, Breakout and More Instantly...
Revance Therapeutics Inc. Company Name:
RVNC Stock Symbol:
NASDAQ Market:
Revance Therapeutics Inc. Website:
- Total net product revenue (DAXXIFY® and RHA® Collection) of $51.7 million, a YoY increase of 13%. - DAXXIFY® net revenue of $22.1 million, after a reduction of $2.0 million related to a consumer coupon program. - Toxin market share increased from 3.0% in Q4’23 to 3...
Conference Call Scheduled for Thursday, May 9, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced that the company will release first quarter 2024 financial results on Thursday, May 9, 2024, after the close of market. Revance will host a corresponding confe...
– Two presentations highlighting data on DAXXIFY® for the treatment of cervical dystonia, including a new analysis from ASPEN trials assessing patient-desired retreatment intervals and one abstract examining the influence of DAXXIFY’s formulation on clinical performance ...